BioSpace News Archive

CG Oncology, Inc. announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 4pm Pacific Standard Time.

AEON Biopharma, Inc. and Priveterra Acquisition Corp. announced the filing of Form S-4 Registration Statement with the U.S. Securities and Exchange Commission regarding the recently announced business combination between the two companies.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced that they have entered into a Research Collaboration and License Agreement with US-based Eli Lilly and Company focused on the discovery and development of novel peptide drug conjugates.

Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.

NANOBIOTIX announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued regarding the company’s New Biologics License Application for NurOwn® for the treatment of ALS.

Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, announced the addition of Dr. Thomas Maldonado as Chief Medical Officer.

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, announced progress against its strategic clinical development priorities, including various updates across its pipeline of infectious disease and central nervous system disease candidates.

ZielBio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas.

Invacare Corporation announced the consummation of an additional draw of $5,500,000 of term loans under to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC, as of December 23, 2022.